Lack of efficacy of imatinib in a patient with metastatic Leydig cell tumor
Lack of efficacy of imatinib in a patient with metastatic Leydig cell tumor
复制标题
DOI：
10.1007/s00280-005-0181-6
复制
发表时间：
2006-11-01
影响因子：
3
通讯作者：
Wirth, Manfred P.
中科院分区：
文献类型：
--
作者：
Froehner, Michael;Beuthien-Baumann, Bettina;Wirth, Manfred P.
Imatinib is a tyrosine kinase inhibitor with activity in gastrointestinal stromal tumor and a variety of other solid and hematological malignancies. Studies in vitro and in a mouse model suggested that the imatinib might also be active in malignant Leydig cell tumor. We report on the-to our knowledge-first treatment experiment with imatinib in a patient with metastatic Leydig cell tumor. Unfortunately, the tumor progressed during treatment.
